Clinical Trials

211 enrolled 29 charts

Gynecologic

Uterine Cervical Neoplasms

NCT03058289 2025-02-27

IT-01

BreastGastrointestinalHead & NeckLymphoidSarcomaThoracic

111 enrolled 21 charts

Diabetes Mellitus, Insulin-Dependent, 12, Bile Duct Neoplasms, Breast Neoplasms, Carcinoma, Carcinoma, Squamous Cell, Colonic Neoplasms, Head and Neck Neoplasms, Liver Neoplasms, Lung Neoplasms, Lymphoma, Neoplasms, Pancreatic Neoplasms, Sarcoma

NCT04171141 2025-01-16

Study to Test the Safety and Tolerability of PF-07062119 in Patients With Selected Advanced or Metastatic Gastrointestinal Tumors.

Phase 1 Terminated

79 enrolled 42 charts

Gastrointestinal

Digestive System Neoplasms, Esophageal Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT02325739 2024-10-21

FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression

BreastDermatologicGastrointestinalGenitourinaryHead & NeckThoracic

172 enrolled 33 charts

Gastrointestinal

Carcinoma, Hepatocellular

NCT03207867 2024-10-09

A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma

Phase 2 Terminated

315 enrolled 73 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Head and Neck Neoplasms, Melanoma, Pancreatic Neoplasms, Spinocerebellar Degenerations, Triple Negative Breast Neoplasms

NCT04323436 2024-10-09

Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations

Phase 2 Terminated

31 enrolled 21 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT03484923 2024-06-18

PLATforM

196 enrolled 22 charts

Dermatologic

Melanoma

NCT02829723 2024-01-18

A Study of BLZ945 Single Agent or BLZ945 in Combination With PDR001 in Advanced Solid Tumors

192 enrolled 77 charts

CNS

Glioblastoma

NCT02608268 2023-12-06

Phase I-Ib/II Study of MBG453 as Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies

DermatologicGenitourinaryThoracic

252 enrolled 67 charts

Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma

NCT04193293 2023-09-21

A Study of Duvelisib in Combination With Pembrolizumab in Head and Neck Cancer

2 enrolled

Head & Neck

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT02795429 2023-07-03

Phase Ib/II Study of INC280 + PDR001 or PDR001 Single Agent in Advanced HCC

89 enrolled 37 charts

Gastrointestinal

Liver Neoplasms

NCT03499899 2023-01-30

A Study of Efficacy and Safety of LAG525 in Combination With Spartalizumab, or With Spartalizumab and Carboplatin, or With Carboplatin, in Patients With Advanced Triple-negative Breast Cancer

88 enrolled 35 charts

Breast

Triple Negative Breast Neoplasms

NCT02404441 2022-08-03

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

BreastDermatologicEndocrineHead & NeckThoracic

319 enrolled 41 charts

Carcinoma, Non-Small-Cell Lung, Melanoma, Triple Negative Breast Neoplasms, Thyroid Carcinoma, Anaplastic

NCT03365791 2022-05-27

PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies

GastrointestinalLymphoidSarcomaThoracic

76 enrolled 14 charts

Adenocarcinoma Of Esophagus, Lymphoma, Sarcoma, Lymphoma, Large B-Cell, Diffuse, Small Cell Lung Carcinoma

NCT02605967 2022-02-10

Safety and Efficacy Study of PDR001 in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma

122 enrolled 28 charts

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms, Recurrence, Disorders of Sex Development

NCT03647488 2022-01-24

Study of Capmatinib and Spartalizumab Combination Therapy vs Docetaxel in Non-small Cell Lung Cancer

18 enrolled 23 charts

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT02807844 2021-08-11

Phase Ib/II Study of MCS110 in Combination With PDR001 in Patients With Advanced Malignancies

BreastDermatologicGastrointestinalGynecologic

141 enrolled 58 charts

Melanoma, Pancreatic Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02955069 2021-04-12

Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)

116 enrolled 24 charts

Neoplasm Metastasis, Neuroectodermal Tumors, Primitive

NCT03351231 2020-08-26

An Investigational Immuno-Therapy Study of Experimental Medication BMS-986242 Given in Combination With Nivolumab in Patients With Advanced Cancer